Institution
Université libre de Bruxelles
Education•Brussels, Belgium•
About: Université libre de Bruxelles is a education organization based out in Brussels, Belgium. It is known for research contribution in the topics: Population & Breast cancer. The organization has 24974 authors who have published 56969 publications receiving 2084303 citations. The organization is also known as: ULB.
Topics: Population, Breast cancer, Context (language use), Receptor, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A fully general approach to the security analysis of continuous-variable quantum key distribution (CV-QKD) is presented, and Gaussian attacks are shown to be optimal against all collective eavesdropping strategies.
Abstract: A fully general approach to the security analysis of continuous-variable quantum key distribution (CV-QKD) is presented. Provided that the quantum channel is estimated via the covariance matrix of the quadratures, Gaussian attacks are shown to be optimal against all collective eavesdropping strategies. The proof is made strikingly simple by combining a physical model of measurement, an entanglement-based description of CV-QKD, and a recent powerful result on the extremality of Gaussian states [M. M. Wolf, Phys. Rev. Lett. 96, 080502 (2006)10.1103/PhysRevLett.96.080502].
461 citations
•
01 Jan 2000TL;DR: In this paper, the aggregate net effect of government funding on business RD Direct funding as well as tax incentives are quantified and shown to be more effective when they are stable over time.
Abstract: This paper attempts to quantify the aggregate net effect of government funding on business RD Direct funding as well as tax incentives are more effective when they are stable over time: firms do not invest in additional RD Direct government funding and RD The stimulating effect of government funding varies with respect to its generosity: it...
461 citations
••
TL;DR: In the present review, the pathways and mechanisms involved in lipoplex- and polyplex-mediated transfection are comparatively addressed and unresolved questions are highlighted.
461 citations
••
TL;DR: Through optimum multidisciplinary management of patients with bone metastases, including the use of bone-targeted treatments such as potent bisphosphonates or denosumab, it has been possible to transform the course of advanced cancer for many patients resulting in a major reduction in skeletal complications, reduced bone pain and improved quality of life.
460 citations
••
TL;DR: The presence of TILs at diagnosis is an independent, positive, prognostic marker in HER2-positive early breast cancer treated with neoadjuvant anti-HER2 agents and chemotherapy for both pCR and EFS end points.
Abstract: Importance The presence of tumor-infiltrating lymphocytes (TILs) is associated with improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer treated with adjuvant trastuzumab and chemotherapy. The prognostic associations in the neoadjuvant setting of other anti-HER2 agents and combinations are unknown. Objective To determine associations between presence of TILs, pathological complete response (pCR), and event-free survival (EFS) end points in patients with early breast cancer treated with trastuzumab, lapatinib, or the combination. Design, Setting, and Participants The NeoALTTO trial (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) randomly assigned 455 women with HER2-positive early-stage breast cancer between January 5, 2008, and May 27, 2010, to 1 of 3 neoadjuvant treatment arms: trastuzumab, lapatinib, or the combination for 6 weeks followed by the addition of weekly paclitaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery. The primary end point used in this study was pCR in the breast and lymph nodes, with a secondary end point of EFS. We evaluated levels of percentage of TILs using hematoxylin-eosin–stained core biopsy sections taken at diagnosis (prior to treatment) in a prospectively defined retrospective analysis. Main Outcomes and Measures Levels of TILs were examined for their associations with efficacy end points adjusted for prognostic clinicopathological factors including PIK3CA genotype. Results Of the 455 patients, 387 (85.1%) tumor samples were used for the present analysis. The median (interquartile range [IQR]) level of TILs was 12.5% (5.0%-30.0%), with levels lower in hormone receptor–positive (10.0% [5.0%-22.5%]) vs hormone receptor–negative (12.5% [3.0%-35.0%]) samples ( P = .02). For the pCR end point, levels of TILs greater than 5% were associated with higher pCR rates independent of treatment group (adjusted odds ratio, 2.60 [95% CI, 1.26-5.39]; P = .01). With a median (IQR) follow-up time of 3.77 (3.50-4.22) years, every 1% increase in TILs was associated with a 3% decrease in the rate of an event (adjusted hazard ratio, 0.97 [95% CI, 0.95-0.99]; P = .002) across all treatment groups. Conclusions and Relevance The presence of TILs at diagnosis is an independent, positive, prognostic marker in HER2-positive early breast cancer treated with neoadjuvant anti-HER2 agents and chemotherapy for both pCR and EFS end points. Trial Registration clinicaltrials.gov Identifier: NCT00553358
459 citations
Authors
Showing all 25206 results
Name | H-index | Papers | Citations |
---|---|---|---|
Karl J. Friston | 217 | 1267 | 217169 |
Yi Chen | 217 | 4342 | 293080 |
David Miller | 203 | 2573 | 204840 |
Jing Wang | 184 | 4046 | 202769 |
H. S. Chen | 179 | 2401 | 178529 |
Jie Zhang | 178 | 4857 | 221720 |
Jasvinder A. Singh | 176 | 2382 | 223370 |
D. M. Strom | 176 | 3167 | 194314 |
J. N. Butler | 172 | 2525 | 175561 |
Andrea Bocci | 172 | 2402 | 176461 |
Bradley Cox | 169 | 2150 | 156200 |
Marc Weber | 167 | 2716 | 153502 |
Hongfang Liu | 166 | 2356 | 156290 |
Guenakh Mitselmakher | 165 | 1951 | 164435 |
Yang Yang | 164 | 2704 | 144071 |